Upgrade to SI Premium - Free Trial

Alkermes (ALKS)

43.24 -0.14 (0.32%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/29/26)

Latest Headlines

Form 4 Alkermes plc. For: Jun 04 Filed by: Gaffin David Joseph June 4, 2026 5:00 PM - SEC Filing Form 144 Alkermes plc. Filed by: Gaffin David Joseph June 4, 2026 4:17 PM - SEC Filing Alkermes to present sleep medicine research at SLEEP 2026 conference June 4, 2026 7:00 AM - StreetInsider Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research June 4, 2026 7:00 AM - BizWire Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference June 3, 2026 4:05 PM - BizWire Form 4 Alkermes plc. For: Jun 01 Filed by: Hopkinson Craig C. June 1, 2026 7:27 PM - SEC Filing Form 144 Alkermes plc. Filed by: Hopkinson Craig C. June 1, 2026 4:30 PM - SEC Filing Form 4 Alkermes plc. For: May 29 Filed by: Parisi Samuel Joseph May 29, 2026 6:03 PM - SEC Filing Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting May 26, 2026 7:00 AM - BizWire Form 4 Alkermes plc. For: May 20 Filed by: Wright Christopher I May 22, 2026 8:08 PM - SEC Filing Form 4 Alkermes plc. For: May 20 Filed by: Wilson Frank Anders May 22, 2026 8:07 PM - SEC Filing Form 4 Alkermes plc. For: May 20 Filed by: snyderman nancy lynn MD May 22, 2026 8:05 PM - SEC Filing Form 4 Alkermes plc. For: May 20 Filed by: MCKEON BRIAN P May 22, 2026 8:04 PM - SEC Filing Form 4 Alkermes plc. For: May 20 Filed by: Lurker Nancy May 22, 2026 8:02 PM - SEC Filing Form 4 Alkermes plc. For: May 20 Filed by: LAURENCIN CATO T May 22, 2026 8:01 PM - SEC Filing Form 4/A Alkermes plc. For: May 20 Filed by: GAYNOR RICHARD May 22, 2026 8:00 PM - SEC Filing Form 4/A Alkermes plc. For: May 20 Filed by: Cooke Shane May 22, 2026 7:58 PM - SEC Filing Form 4 Alkermes plc. For: May 20 Filed by: GAYNOR RICHARD May 22, 2026 4:59 PM - SEC Filing Form 4 Alkermes plc. For: May 20 Filed by: Cooke Shane May 22, 2026 4:58 PM - SEC Filing Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences May 21, 2026 7:00 AM - BizWire Form 8-K Alkermes plc. For: May 20 May 20, 2026 4:11 PM - SEC Filing Form SCHEDULE 13G/A Alkermes plc. Filed by: PRICE T ROWE ASSOCIATES INC /MD/ May 15, 2026 10:09 AM - SEC Filing Form DEFA14A Alkermes plc. May 13, 2026 5:03 PM - SEC Filing Alkermes (ALKS) PT Raised to $48 at Baird May 13, 2026 6:23 AM - StreetInsider TD Cowen on Alkermes (ALKS): 'Lumryz's true once nightly profile should support uptake in a large market' May 12, 2026 9:30 AM - StreetInsider Form 8-K Alkermes plc. For: May 12 May 12, 2026 7:08 AM - SEC Filing Alkermes reports positive phase 3 trial results for LUMRYZ in sleep disorder May 12, 2026 7:00 AM - StreetInsider Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia May 12, 2026 7:00 AM - BizWire Alkermes (ALKS) PT Raised to $48 at UBS May 6, 2026 9:22 AM - StreetInsider Alkermes (ALKS) PT Raised to $44 at Wells Fargo May 6, 2026 8:46 AM - StreetInsider Alkermes (ALKS) PT Raised to $50 at Needham May 6, 2026 7:22 AM - StreetInsider Form 10-Q Alkermes plc. For: Mar 31 May 5, 2026 4:31 PM - SEC Filing Alkermes (ALKS) PT Raised to $45 at Stifel May 5, 2026 12:28 PM - StreetInsider Alkermes (ALKS) Tops Q1 EPS by 14c; offers guidance May 5, 2026 7:13 AM - StreetInsider Form 8-K Alkermes plc. For: May 05 May 5, 2026 7:05 AM - SEC Filing Alkermes plc Reports First Quarter 2026 Financial Results May 5, 2026 7:00 AM - BizWire Form 4 Alkermes plc. For: May 04 Filed by: Gaffin David Joseph May 4, 2026 8:43 PM - SEC Filing Form 144 Alkermes plc. Filed by: Gaffin David Joseph May 4, 2026 4:31 PM - SEC Filing Form 4 Alkermes plc. For: May 01 Filed by: Hopkinson Craig C. May 1, 2026 9:05 PM - SEC Filing Form 8-K/A Alkermes plc. For: Feb 12 May 1, 2026 4:52 PM - SEC Filing Form 144 Alkermes plc. Filed by: Hopkinson Craig C. May 1, 2026 4:22 PM - SEC Filing Form SCHEDULE 13G Alkermes plc. Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC April 28, 2026 2:46 PM - SEC Filing Form SCHEDULE 13G Alkermes plc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC April 28, 2026 11:18 AM - SEC Filing Alkermes to Report First Quarter Financial Results on May 5, 2026 April 21, 2026 4:05 PM - BizWire Alkermes to present narcolepsy drug data at neurology meeting April 16, 2026 7:00 AM - StreetInsider Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting April 16, 2026 7:00 AM - BizWire Alkermes publishes 56-week LYBALVI analysis on schizophrenia symptoms April 14, 2026 7:00 AM - StreetInsider Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry April 14, 2026 7:00 AM - BizWire Form 4 Alkermes plc. For: Apr 11 Filed by: Lurker Nancy April 13, 2026 5:10 PM - SEC Filing Alkermes (ALKS) PT Raised to $53 at Mizuho April 10, 2026 6:38 AM - StreetInsider Alkermes (ALKS) PT Raised to $36 at BofA Securities April 9, 2026 8:56 AM - StreetInsider Alkermes (ALKS) PT Lowered to $44 at RBC Capital April 7, 2026 9:05 AM - StreetInsider Form 4 Alkermes plc. For: Apr 06 Filed by: Gaffin David Joseph April 6, 2026 8:23 PM - SEC Filing Form ARS Alkermes plc. For: Dec 31 April 6, 2026 5:17 PM - SEC Filing Form DEFA14A Alkermes plc. April 6, 2026 5:12 PM - SEC Filing Form DEF 14A Alkermes plc. For: May 20 April 6, 2026 5:06 PM - SEC Filing Form 144 Alkermes plc. Filed by: Gaffin David Joseph April 6, 2026 4:17 PM - SEC Filing Form 4 Alkermes plc. For: Apr 01 Filed by: Hopkinson Craig C. April 1, 2026 6:59 PM - SEC Filing Form 144 Alkermes plc. Filed by: Hopkinson Craig C. April 1, 2026 4:14 PM - SEC Filing Alkermes initiates phase 3 trials for narcolepsy drug alixorexton April 1, 2026 7:00 AM - StreetInsider Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2 April 1, 2026 7:00 AM - BizWire Form PRE 14A Alkermes plc. For: May 20 March 27, 2026 5:23 PM - SEC Filing Form SCHEDULE 13G/A Alkermes plc. Filed by: VANGUARD GROUP INC March 26, 2026 1:07 PM - SEC Filing Alkermes (ALKS) PT Lowered to $43 at Piper Sandler March 24, 2026 8:52 AM - StreetInsider Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program March 12, 2026 7:00 AM - BizWire Alkermes to Present at the Stifel 2026 Virtual CNS Forum March 10, 2026 4:00 PM - BizWire Truist Securities Reiterates Buy Rating on Alkermes (ALKS): "remains one of our highest conviction BUY rated stocks" March 10, 2026 8:24 AM - StreetInsider Full Article List